1.Assessment of abdominal visceral fat measured by dual bioelectrical impedance analysis in rugby football players
Chiaki Yamashita ; Kayoko Yamazaki ; Yuri Kanesada ; Takashi Miyawaki ; Reiko Nakayama ; Shingo Okazaki ; Naoko Komenami
Japanese Journal of Physical Fitness and Sports Medicine 2015;64(2):251-259
Visceral fat accumulation is a notable risk factor in the incidence of lifestyle-related diseases such as metabolic and circulatory disorders. In this study, we measured visceral fat area (VFA) and subcutaneous fat area (SFA) in rugby football players by using dual bioelectrical impedance analysis, as well as other metabolic and circulatory parameters. A total of 28 male players (15 forwards, 13 backs; mean age±SD: 23±4 years) participated in this study. VFA and SFA were significantly correlated with body weight. Thus, heavier players had higher VFA and SFA as well as higher body weight. In addition, VFA was significantly correlated with various blood parameters such as alanine aminotransferase, gamma-glutamyl transpeptidase, and triglyceride. Six of the 28 players met the criteria for visceral obesity, defined as both body mass index ≥25 kg/m2 and VFA ≥100 cm2. In some of these players, blood parameters such as high-density lipoprotein cholesterol <40 mg/dL, triglyceride ≥150 mg/dL, or systolic blood pressure ≥130 mmHg indicated elevated risk for metabolic syndrome. These findings suggest that in athletes like heavier rugby football players, abdominal visceral fat accumulation may indicate risk of lifestyle-related diseases.
2.Correction: Efficacy and Safety of Long-Term Administration of Esomeprazole in Japanese Pediatric Patients Aged 1–14 Years with Chronic Gastric Acid-Related Disease
Masaaki MORI ; Yoshiko NAKAYAMA ; Shigeo NISHIMATA ; Tadafumi YOKOYAMA ; Ryo MATSUOKA ; Reiko HATORI ; Masaki SHIMIZU ; Katsuhiro ARAI ; Yuri ETANI ; Tsuyoshi SOGO ; Tomoko ISHIZU ; Masahiro NII ; Ryosuke NAKASHIMA ; Toshiaki SHIMIZU
Pediatric Gastroenterology, Hepatology & Nutrition 2024;27(6):383-384
3.Efficacy and Safety of Long-Term Administration of Esomeprazole in Japanese Pediatric Patients Aged 1–14 Years with Chronic Gastric Acid-Related Disease
Masaaki MORI ; Yoshiko NAKAYAMA ; Shigeo NISHIMATA ; Tadafumi YOKOYAMA ; Ryo MATSUOKA ; Reiko HATORI ; Masaki SHIMIZU ; Katsuhiro ARAI ; Yuri ETANI ; Tsuyoshi SOGO ; Tomoko ISHIZU ; Masahiro NII ; Ryosuke NAKASHIMA ; Toshiaki SHIMIZU
Pediatric Gastroenterology, Hepatology & Nutrition 2024;27(5):274-285
Purpose:
To evaluate prolonged esomeprazole use in Japanese pediatric patients for reflux esophagitis (RE) maintenance therapy and prevention of gastric (GU) and/or duodenal ulcers (DU) while using non-steroidal anti-inflammatory drugs (NSAIDs) or low-dose aspirin (LDA).
Methods:
This multicenter, open-label, parallel-group, phase III study (NCT03553563) included patients who were administered esomeprazole according to body weight (10 mg/day [Groups 1 and 3] and up to 20 mg/day [Groups 2 and 4] for patients weighing 10–20 kg and ≥20 kg, respectively). Efficacy outcomes for Groups 1 and 2 (maintenance therapy for healed RE) and Groups 3 and 4 (prevention of long-term NSAID/LDA use-associated GU/DU) were the presence/absence of RE relapse and GU/DU recurrence, respectively.
Results:
Esomeprazole as maintenance therapy was associated with a low RE recurrence rate, independent of body weight or dosage. Recurrence rates of RE were 0.0% and 5.3% for Groups 1 and 2, respectively. In patients previously diagnosed with GU and/or DU due to long-term NSAID/LDA use, the recurrence rates of GU/DU during weeks 0–32 were 11.1% and 0.0% in Groups 3 and 4, respectively.
Conclusion
Long-term use of 10- or 20-mg, once-daily esomeprazole demonstrated a favorable benefit-risk balance in preventing RE and suppressing recurrence of GU and/or DU secondary to NSAID or LDA therapy in Japanese pediatric patients. No new safety concerns were identified. Esomeprazole may be a viable option for managing RE and preventing GU and DU in Japanese pediatric patients.
4.Correction: Efficacy and Safety of Long-Term Administration of Esomeprazole in Japanese Pediatric Patients Aged 1–14 Years with Chronic Gastric Acid-Related Disease
Masaaki MORI ; Yoshiko NAKAYAMA ; Shigeo NISHIMATA ; Tadafumi YOKOYAMA ; Ryo MATSUOKA ; Reiko HATORI ; Masaki SHIMIZU ; Katsuhiro ARAI ; Yuri ETANI ; Tsuyoshi SOGO ; Tomoko ISHIZU ; Masahiro NII ; Ryosuke NAKASHIMA ; Toshiaki SHIMIZU
Pediatric Gastroenterology, Hepatology & Nutrition 2024;27(6):383-384
5.Efficacy and Safety of Long-Term Administration of Esomeprazole in Japanese Pediatric Patients Aged 1–14 Years with Chronic Gastric Acid-Related Disease
Masaaki MORI ; Yoshiko NAKAYAMA ; Shigeo NISHIMATA ; Tadafumi YOKOYAMA ; Ryo MATSUOKA ; Reiko HATORI ; Masaki SHIMIZU ; Katsuhiro ARAI ; Yuri ETANI ; Tsuyoshi SOGO ; Tomoko ISHIZU ; Masahiro NII ; Ryosuke NAKASHIMA ; Toshiaki SHIMIZU
Pediatric Gastroenterology, Hepatology & Nutrition 2024;27(5):274-285
Purpose:
To evaluate prolonged esomeprazole use in Japanese pediatric patients for reflux esophagitis (RE) maintenance therapy and prevention of gastric (GU) and/or duodenal ulcers (DU) while using non-steroidal anti-inflammatory drugs (NSAIDs) or low-dose aspirin (LDA).
Methods:
This multicenter, open-label, parallel-group, phase III study (NCT03553563) included patients who were administered esomeprazole according to body weight (10 mg/day [Groups 1 and 3] and up to 20 mg/day [Groups 2 and 4] for patients weighing 10–20 kg and ≥20 kg, respectively). Efficacy outcomes for Groups 1 and 2 (maintenance therapy for healed RE) and Groups 3 and 4 (prevention of long-term NSAID/LDA use-associated GU/DU) were the presence/absence of RE relapse and GU/DU recurrence, respectively.
Results:
Esomeprazole as maintenance therapy was associated with a low RE recurrence rate, independent of body weight or dosage. Recurrence rates of RE were 0.0% and 5.3% for Groups 1 and 2, respectively. In patients previously diagnosed with GU and/or DU due to long-term NSAID/LDA use, the recurrence rates of GU/DU during weeks 0–32 were 11.1% and 0.0% in Groups 3 and 4, respectively.
Conclusion
Long-term use of 10- or 20-mg, once-daily esomeprazole demonstrated a favorable benefit-risk balance in preventing RE and suppressing recurrence of GU and/or DU secondary to NSAID or LDA therapy in Japanese pediatric patients. No new safety concerns were identified. Esomeprazole may be a viable option for managing RE and preventing GU and DU in Japanese pediatric patients.
6.Correction: Efficacy and Safety of Long-Term Administration of Esomeprazole in Japanese Pediatric Patients Aged 1–14 Years with Chronic Gastric Acid-Related Disease
Masaaki MORI ; Yoshiko NAKAYAMA ; Shigeo NISHIMATA ; Tadafumi YOKOYAMA ; Ryo MATSUOKA ; Reiko HATORI ; Masaki SHIMIZU ; Katsuhiro ARAI ; Yuri ETANI ; Tsuyoshi SOGO ; Tomoko ISHIZU ; Masahiro NII ; Ryosuke NAKASHIMA ; Toshiaki SHIMIZU
Pediatric Gastroenterology, Hepatology & Nutrition 2024;27(6):383-384
7.Efficacy and Safety of Long-Term Administration of Esomeprazole in Japanese Pediatric Patients Aged 1–14 Years with Chronic Gastric Acid-Related Disease
Masaaki MORI ; Yoshiko NAKAYAMA ; Shigeo NISHIMATA ; Tadafumi YOKOYAMA ; Ryo MATSUOKA ; Reiko HATORI ; Masaki SHIMIZU ; Katsuhiro ARAI ; Yuri ETANI ; Tsuyoshi SOGO ; Tomoko ISHIZU ; Masahiro NII ; Ryosuke NAKASHIMA ; Toshiaki SHIMIZU
Pediatric Gastroenterology, Hepatology & Nutrition 2024;27(5):274-285
Purpose:
To evaluate prolonged esomeprazole use in Japanese pediatric patients for reflux esophagitis (RE) maintenance therapy and prevention of gastric (GU) and/or duodenal ulcers (DU) while using non-steroidal anti-inflammatory drugs (NSAIDs) or low-dose aspirin (LDA).
Methods:
This multicenter, open-label, parallel-group, phase III study (NCT03553563) included patients who were administered esomeprazole according to body weight (10 mg/day [Groups 1 and 3] and up to 20 mg/day [Groups 2 and 4] for patients weighing 10–20 kg and ≥20 kg, respectively). Efficacy outcomes for Groups 1 and 2 (maintenance therapy for healed RE) and Groups 3 and 4 (prevention of long-term NSAID/LDA use-associated GU/DU) were the presence/absence of RE relapse and GU/DU recurrence, respectively.
Results:
Esomeprazole as maintenance therapy was associated with a low RE recurrence rate, independent of body weight or dosage. Recurrence rates of RE were 0.0% and 5.3% for Groups 1 and 2, respectively. In patients previously diagnosed with GU and/or DU due to long-term NSAID/LDA use, the recurrence rates of GU/DU during weeks 0–32 were 11.1% and 0.0% in Groups 3 and 4, respectively.
Conclusion
Long-term use of 10- or 20-mg, once-daily esomeprazole demonstrated a favorable benefit-risk balance in preventing RE and suppressing recurrence of GU and/or DU secondary to NSAID or LDA therapy in Japanese pediatric patients. No new safety concerns were identified. Esomeprazole may be a viable option for managing RE and preventing GU and DU in Japanese pediatric patients.
8.Correction: Efficacy and Safety of Long-Term Administration of Esomeprazole in Japanese Pediatric Patients Aged 1–14 Years with Chronic Gastric Acid-Related Disease
Masaaki MORI ; Yoshiko NAKAYAMA ; Shigeo NISHIMATA ; Tadafumi YOKOYAMA ; Ryo MATSUOKA ; Reiko HATORI ; Masaki SHIMIZU ; Katsuhiro ARAI ; Yuri ETANI ; Tsuyoshi SOGO ; Tomoko ISHIZU ; Masahiro NII ; Ryosuke NAKASHIMA ; Toshiaki SHIMIZU
Pediatric Gastroenterology, Hepatology & Nutrition 2024;27(6):383-384
9.Efficacy and Safety of Long-Term Administration of Esomeprazole in Japanese Pediatric Patients Aged 1–14 Years with Chronic Gastric Acid-Related Disease
Masaaki MORI ; Yoshiko NAKAYAMA ; Shigeo NISHIMATA ; Tadafumi YOKOYAMA ; Ryo MATSUOKA ; Reiko HATORI ; Masaki SHIMIZU ; Katsuhiro ARAI ; Yuri ETANI ; Tsuyoshi SOGO ; Tomoko ISHIZU ; Masahiro NII ; Ryosuke NAKASHIMA ; Toshiaki SHIMIZU
Pediatric Gastroenterology, Hepatology & Nutrition 2024;27(5):274-285
Purpose:
To evaluate prolonged esomeprazole use in Japanese pediatric patients for reflux esophagitis (RE) maintenance therapy and prevention of gastric (GU) and/or duodenal ulcers (DU) while using non-steroidal anti-inflammatory drugs (NSAIDs) or low-dose aspirin (LDA).
Methods:
This multicenter, open-label, parallel-group, phase III study (NCT03553563) included patients who were administered esomeprazole according to body weight (10 mg/day [Groups 1 and 3] and up to 20 mg/day [Groups 2 and 4] for patients weighing 10–20 kg and ≥20 kg, respectively). Efficacy outcomes for Groups 1 and 2 (maintenance therapy for healed RE) and Groups 3 and 4 (prevention of long-term NSAID/LDA use-associated GU/DU) were the presence/absence of RE relapse and GU/DU recurrence, respectively.
Results:
Esomeprazole as maintenance therapy was associated with a low RE recurrence rate, independent of body weight or dosage. Recurrence rates of RE were 0.0% and 5.3% for Groups 1 and 2, respectively. In patients previously diagnosed with GU and/or DU due to long-term NSAID/LDA use, the recurrence rates of GU/DU during weeks 0–32 were 11.1% and 0.0% in Groups 3 and 4, respectively.
Conclusion
Long-term use of 10- or 20-mg, once-daily esomeprazole demonstrated a favorable benefit-risk balance in preventing RE and suppressing recurrence of GU and/or DU secondary to NSAID or LDA therapy in Japanese pediatric patients. No new safety concerns were identified. Esomeprazole may be a viable option for managing RE and preventing GU and DU in Japanese pediatric patients.
10.Correction: Efficacy and Safety of Long-Term Administration of Esomeprazole in Japanese Pediatric Patients Aged 1–14 Years with Chronic Gastric Acid-Related Disease
Masaaki MORI ; Yoshiko NAKAYAMA ; Shigeo NISHIMATA ; Tadafumi YOKOYAMA ; Ryo MATSUOKA ; Reiko HATORI ; Masaki SHIMIZU ; Katsuhiro ARAI ; Yuri ETANI ; Tsuyoshi SOGO ; Tomoko ISHIZU ; Masahiro NII ; Ryosuke NAKASHIMA ; Toshiaki SHIMIZU
Pediatric Gastroenterology, Hepatology & Nutrition 2024;27(6):383-384